Saturday 17 October 2026
Export ITGR’s income statement to Excel — free account
Integer Holdings Corporation
ITGR Healthcare Medical Devices
Integer Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 7.98% from fiscal 2024. In the quarter to June 2026, revenue fell 2.60%, EPS fell 34.9%, free cash flow grew 48.8% and total debt rose 4.96%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
126.70
0.02
−0.02%
Follow ITGR
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 18.10 | 29.00 | 42.50 | 67.72 | 46.01 | 73.32 | 50.05 | 63.00 | 94.56 | 62.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 47.77 | 55.20 | 90.03 | 92.62 | 99.95 | 101.61 | 88.58 | 100.99 | 142.76 | 146.36 | |||||
| People | |||||||||||||||
| People | Employees | 9,400 | 9,700 | 8,250 | 8,250 | 7,500 | 9,000 | 10,000 | 10,500 | 11,000 | 11,000 | ||||
| Revenue/emp, $m | 0.11 | 0.12 | 0.15 | 0.15 | 0.14 | 0.14 | 0.13 | 0.15 | 0.16 | 0.17 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 1,076 | 1,136 | 1,215 | 1,258 | 1,073 | 1,221 | 1,331 | 1,556 | 1,717 | 1,854 | ||||
| Gross margin, % | 31.40 | 31.16 | 29.85 | 28.22 | 26.62 | 27.60 | 25.97 | 26.35 | 26.74 | 26.99 | |||||
| EBT | 28 | 49 | 61 | 105 | 86 | 101 | 69 | 105 | 148 | 125 | |||||
| EBT margin, % | 2.62 | 4.34 | 5.03 | 8.36 | 8.03 | 8.28 | 5.16 | 6.77 | 8.60 | 6.76 | |||||
| Net income | 6 | 67 | 168 | 96 | 77 | 97 | 66 | 91 | 120 | 103 | |||||
| Depreciation | 98 | 114 | 138 | 86 | 84 | 88 | 94 | 107 | 115 | 138 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 34.94 | 36.18 | 37.81 | 38.56 | 32.68 | 37.01 | 40.19 | 46.69 | 51.09 | 53.37 | ||||
| Earnings | 0.19 | 2.12 | 5.23 | 2.95 | 2.35 | 2.93 | 2.00 | 2.72 | 3.57 | 2.96 | |||||
| Cash flow | 3.43 | 4.76 | 5.21 | 5.07 | 5.52 | 4.75 | 3.51 | 5.41 | 6.11 | 5.65 | |||||
| Capex | (1.89) | (1.49) | (1.35) | (1.48) | (1.56) | (1.61) | (2.24) | (3.60) | (3.14) | (2.62) | |||||
| Free cash flow | 1.54 | 3.27 | 3.85 | 3.59 | 3.96 | 3.14 | 1.28 | 1.81 | 2.96 | 3.03 | |||||
| Book value | 23.56 | 28.45 | 33.00 | 35.32 | 38.70 | 41.06 | 42.79 | 45.59 | 48.19 | 50.28 | |||||
| Shares, m | 31 | 31 | 32 | 33 | 33 | 33 | 33 | 33 | 34 | 35 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 155.53 | 21.62 | 14.67 | 27.17 | 34.55 | 29.21 | 34.24 | 36.12 | 37.22 | 26.86 | ||||
| P/S | 0.85 | 1.25 | 2.02 | 2.09 | 2.48 | 2.31 | 1.70 | 2.10 | 2.59 | 1.47 | |||||
| P/B | 1.25 | 1.60 | 2.31 | 2.28 | 2.10 | 2.08 | 1.60 | 2.15 | 2.75 | 1.56 | |||||
| EV/Sales | 2.41 | 2.64 | 2.76 | 2.72 | 3.12 | 2.98 | 2.39 | 2.72 | 3.16 | 2.12 | |||||
| EV/FCF | 54.77 | 29.24 | 27.07 | 29.23 | 25.76 | 36.77 | 84.31 | 75.98 | 54.83 | 37.66 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | 106 | 149 | 167 | 165 | 181 | 157 | 116 | 180 | 205 | 196 | ||||
| Capex | (58) | (47) | (44) | (48) | (51) | (53) | (74) | (120) | (106) | (91) | |||||
| Free cash flow | 47 | 103 | 124 | 117 | 130 | 104 | 42 | 60 | 100 | 105 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 332 | 323 | 252 | 236 | 257 | 293 | 335 | 397 | 444 | 538 | ||||
| Total debt | 1,730 | 1,609 | 926 | 815 | 731 | 836 | 933 | 970 | 1,014 | 1,214 | |||||
| Net debt | 1,678 | 1,572 | 900 | 801 | 682 | 818 | 909 | 947 | 967 | 1,197 | |||||
| Shareholders’ equity | 725 | 893 | 1,060 | 1,152 | 1,271 | 1,355 | 1,417 | 1,519 | 1,619 | 1,747 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | 0.21 | 2.35 | 6.49 | 4.12 | 3.27 | 3.91 | 2.47 | 3.16 | 3.98 | 3.17 | ||||
| ROIC | 2.42 | 3.19 | 4.96 | 5.04 | 3.86 | 3.90 | 3.03 | 4.14 | 5.03 | 4.70 | |||||
| ROE | 0.76 | 8.24 | 17.19 | 8.71 | 6.38 | 7.37 | 4.79 | 6.17 | 7.64 | 6.11 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Integer Holdings Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BRKR Bruker Corporation | $8.6B | — (loss-making) | 55.7× | +5.15% (above 0%: growing) | n/m | +28.63% (above 0%: growing) | 49.61% | (7.79%) | Compare |
| HAE Haemonetics Corporation | $5.5B | 57.7× | 18.0× | +5.60% (above 0%: growing) | +2.86% (above 0%: growing) | +220.38% (above 0%: growing) | 59.76% | 16.93% | Compare |
| LIVN LivaNova PLC | $4.3B | 22.5× | 26.0× | +10.80% (above 0%: growing) | +296.00% (above 0%: growing) | −26.66% (below 0%: shrinking) | 70.07% | 12.67% | Compare |
| ITGR Integer Holdings Corporation | $4.3B | 34.3× | 27.6× | −2.60% (below 0%: shrinking) | −34.91% (below 0%: shrinking) | +48.81% (above 0%: growing) | 24.34% | 7.44% | |
| IRTC iRhythm Holdings, Inc. | $3.6B | — (loss-making) | — (loss-making) | +20.08% (above 0%: growing) | n/m | +116.98% (above 0%: growing) | 72.80% | (1.13%) | Compare |
| NEOG Neogen Corporation | $2.7B | — (loss-making) | — (loss-making) | +6.51% (above 0%: growing) | n/m | +135.75% (above 0%: growing) | 47.35% | (0.81%) | Compare |
| TMDX TransMedics Group, Inc. | $2.7B | 16.0× | 34.1× | +20.70% (above 0%: growing) | −59.22% (below 0%: shrinking) | −87.62% (below 0%: shrinking) | 59.59% | 12.50% | Compare |
| UFPT UFP Technologies, Inc. | $2.3B | 31.2× | 23.6× | +15.07% (above 0%: growing) | +20.63% (above 0%: growing) | −35.77% (below 0%: shrinking) | 29.27% | 16.15% | Compare |
| BFLY Butterfly Network, Inc. | $2.1B | — (loss-making) | — (loss-making) | +39.47% (above 0%: growing) | n/m | −113.85% (below 0%: shrinking) | 71.41% | (41.90%) | Compare |
| Median of peers | $3.1B | 26.8× | 26.0× | +12.94% | +11.75% | +0.98% | 59.68% | 5.85% |
Integer Holdings Corporation (ITGR) key facts
- Strength: Integer Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 7.98% from fiscal 2024.
- Integer Holdings Corporation (ITGR) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
- As of October 16, 2026, ITGR traded at $126.70, a market capitalization of $4.3 billion.
- Return on equity was 6.11% and debt-to-equity 0.75.
- Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 2.34 (grey zone) for fiscal 2025.